Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI Worldwide, MilanCPhI Worldwide, Milan
Not Confirmed
Not Confirmed
08-10 October, 2024
Discovery on TargetDiscovery on Target
Not Confirmed
Not Confirmed
30 September-03 October, 2024
Not Confirmed
Not Confirmed
30 September-02 October, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI Worldwide, MilanCPhI Worldwide, Milan
Industry Trade Show
Not Confirmed
08-10 October, 2024
Discovery on TargetDiscovery on Target
Industry Trade Show
Not Confirmed
30 September-03 October, 2024
Industry Trade Show
Not Confirmed
30 September-02 October, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/ice-is-pioneering-sustainability-innovation-in-bile-acid-research-for-neurodegenerative-diseases
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/2024-us-elections-harris-trump-differ-on-abortion-rights-aca-public-health-spends-agree-on-need-to-cut-drug-prices
24 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/24/2952045/0/en/Atsena-Therapeutics-to-Present-at-Chardan-s-8th-Annual-Genetic-Medicines-Conference.html
17 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/17/2947307/0/en/Atsena-Therapeutics-Receives-Orphan-Drug-Designation-from-the-U-S-FDA-for-ATSN-201-Gene-Therapy-to-Treat-X-linked-Retinoschisis.html
05 Sep 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/09/05/2941896/0/en/Atsena-Therapeutics-Announces-12-Month-Safety-and-Efficacy-Data-from-Phase-I-II-Clinical-Trial-of-ATSN-101-in-LCA1-Published-in-The-Lancet.html
14 Aug 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/08/14/2929958/0/en/Atsena-Therapeutics-Receives-Rare-Pediatric-Disease-Designation-from-the-U-S-FDA-for-ATSN-201-Gene-Therapy-to-Treat-X-linked-Retinoschisis.html
01 May 2024
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2024/05/01/2873117/0/en/Atsena-Therapeutics-Announces-Positive-Clinical-Data-from-the-First-Cohort-of-Phase-I-II-Trial-Evaluating-ATSN-201-Gene-Therapy-for-the-Treatment-of-X-linked-Retinoschisis-XLRS.html
13 Mar 2024
// GLOBENEWSWIRE
https://www.globenewswire.com//news-release/2024/03/13/2845328/0/en/Atsena-Therapeutics-Announces-Initiation-of-Dosing-in-Second-Cohort-of-Phase-I-II-Clinical-Trial-Evaluating-ATSN-201-Gene-Therapy-for-the-Treatment-of-X-linked-Retinoschisis-XLRS.html
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?